MabVax Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch MBVXQ and buy or sell other stocks, ETFs, and their options commission-free!

About MBVXQ

MabVax Therapeutics Holdings, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. The company was founded on July 8, 2014 and is headquartered in San Diego, CA. 

CEO
John David Hansen
CEOJohn David Hansen
Employees
Employees
Headquarters
Clinton, Arkansas
HeadquartersClinton, Arkansas
Founded
2014
Founded2014
Employees
Employees

MBVXQ Key Statistics

Market cap
216.90K
Market cap216.90K
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
976.70
Average volume976.70
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.139
52 Week high$0.139
52 Week low
$0.0037
52 Week low$0.0037

Stock Snapshot

The current MabVax Therapeutics(MBVXQ) stock price is $0.02, with a market capitalization of 216.9K.

During the trading day, MabVax Therapeutics(MBVXQ) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for MabVax Therapeutics(MBVXQ) stock has reached 0, versus its average volume of 976.7.

Over the past 52 weeks, MabVax Therapeutics(MBVXQ) stock has traded between a high of $0.14 and a low of $0.00.

Over the past 52 weeks, MabVax Therapeutics(MBVXQ) stock has traded between a high of $0.14 and a low of $0.00.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.